Approval of pembrolizumab for first-line treatment of microsatellite instability-high/mismatch repair deficient colorectal cancer: estimation of incremental benefit based on restricted mean survival time

2021 ◽  
Vol 33 (5) ◽  
pp. 763-763
Author(s):  
Andrea Messori
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Instability ◽  
Survival Time ◽  
Mismatch Repair ◽  
Line Treatment ◽  
First Line ◽  
Incremental Benefit ◽  
Mean Survival Time ◽  
Restricted Mean Survival Time ◽  
First Line Treatment

scholarly journals Pembrolizumab (Keytruda)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Microsatellite Instability ◽  
Mismatch Repair ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Line Treatment ◽  
First Line ◽  
Clinician Perspectives ◽  
First Line Treatment

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda) 200 mg administered intravenously Indication: As monotherapy, for the first-line treatment of adults with metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer

scholarly journals Pembrolizumab (Keytruda)

2021 ◽  
Vol 1 (7) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Instability ◽  
Mismatch Repair ◽  
Performance Status ◽  
Prior Treatment ◽  
Line Treatment ◽  
First Line ◽  
Good Performance Status ◽  
First Line Treatment

CADTH recommends that Keytruda (pembrolizumab) should be reimbursed as monotherapy for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer if certain conditions are met. Keytruda should only be reimbursed if prescribed by clinicians with experience in immuno-oncology and treating colorectal cancer, and if the price of the drug is reduced. Keytruda should only be covered to treat patients who have not received prior treatment for metastatic MSI-H/dMMR colorectal cancer and have a good performance status at the start of treatment with pembrolizumab.

Sign in / Sign up

Export Citation Format

Share Document